These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
50 related articles for article (PubMed ID: 9715090)
1. [Interleukin-6 acts in different ways via soluble and membrane-bound receptors]. Igaz P; Tóth S; Madurka I; Falus A Orv Hetil; 1998 Jul; 139(29):1741-4. PubMed ID: 9715090 [TBL] [Abstract][Full Text] [Related]
2. Soluble interleukin 6 (IL-6) receptor influences the expression of the protooncogene junB and the production of fibrinogen in the HepG2 human hepatoma cell line and primary rat hepatocytes. Igaz P; Tóth S; Rose-John S; Madurka I; Fejér G; Szalai C; Falus A Cytokine; 1998 Aug; 10(8):620-6. PubMed ID: 9722935 [TBL] [Abstract][Full Text] [Related]
3. Soluble IL-6 receptor potentiates the antagonistic activity of soluble gp130 on IL-6 responses. Müller-Newen G; Küster A; Hemmann U; Keul R; Horsten U; Martens A; Graeve L; Wijdenes J; Heinrich PC J Immunol; 1998 Dec; 161(11):6347-55. PubMed ID: 9834125 [TBL] [Abstract][Full Text] [Related]
4. Interleukin-6 N-terminal peptides modulate the expression of junB protooncogene and the production of fibrinogen in HepG2 cells. Bosze S; Hudecz F; Igaz P; Ortutay Z; Csík G; Falus A; Tóth S Biol Chem; 2003 Mar; 384(3):409-21. PubMed ID: 12715892 [TBL] [Abstract][Full Text] [Related]
5. IL-6 transsignaling: the in vivo consequences. Jones SA; Richards PJ; Scheller J; Rose-John S J Interferon Cytokine Res; 2005 May; 25(5):241-53. PubMed ID: 15871661 [TBL] [Abstract][Full Text] [Related]
6. Interleukin-6 trans-signalling in chronic inflammation and cancer. Scheller J; Ohnesorge N; Rose-John S Scand J Immunol; 2006 May; 63(5):321-9. PubMed ID: 16640655 [TBL] [Abstract][Full Text] [Related]
7. Activation of the signal transducer glycoprotein 130 by both IL-6 and IL-11 requires two distinct binding epitopes. Kurth I; Horsten U; Pflanz S; Dahmen H; Küster A; Grötzinger J; Heinrich PC; Müller-Newen G J Immunol; 1999 Feb; 162(3):1480-7. PubMed ID: 9973404 [TBL] [Abstract][Full Text] [Related]
8. Physician Education: The Erythropoietin Receptor and Signal Transduction. Yoshimura A; Arai K Oncologist; 1996; 1(5):337-339. PubMed ID: 10388012 [TBL] [Abstract][Full Text] [Related]
9. Significance of autologous interleukin-6 production in the HA22T/VGH cell model of hepatocellular carcinoma. Labbozzetta M; Notarbartolo M; Poma P; Giannitrapani L; Cervello M; Montalto G; D'Alessandro N Ann N Y Acad Sci; 2006 Nov; 1089():268-75. PubMed ID: 17261774 [TBL] [Abstract][Full Text] [Related]
10. Interleukin-6 receptor signaling. II. Bio-availability of interleukin-6 in serum. Gaillard J; Pugnière M; Tresca J; Mani J; Klein B; Brochier J Eur Cytokine Netw; 1999 Sep; 10(3):337-44. PubMed ID: 10477390 [TBL] [Abstract][Full Text] [Related]
11. Characterization of soluble gp130 released by melanoma cell lines: A polyvalent antagonist of cytokines from the interleukin 6 family. Montero-Julian FA; Brailly H; Sautès C; Joyeux I; Dorval T; Mosseri V; Yasukawa K; Wijdenes J; Adler A; Gorin I; Fridman WH; Tartour E Clin Cancer Res; 1997 Aug; 3(8):1443-51. PubMed ID: 9815830 [TBL] [Abstract][Full Text] [Related]
12. IL-6 transsignalling modulates the early effector phase of EAE and targets the blood-brain barrier. Linker RA; Lühder F; Kallen KJ; Lee DH; Engelhardt B; Rose-John S; Gold R J Neuroimmunol; 2008 Dec; 205(1-2):64-72. PubMed ID: 18950871 [TBL] [Abstract][Full Text] [Related]
13. Factors influencing the effect of the soluble IL-6 receptor on IL-6 responses in HepG2 hepatocytes. Paysant J; Blanqué R; Vasse M; Soria C; Soria J; Gardner CR Cytokine; 2000 Jun; 12(6):774-9. PubMed ID: 10843763 [TBL] [Abstract][Full Text] [Related]
15. Interleukin-6 receptor signaling. I. gp80 and gp130 receptor interaction in the absence of interleukin-6. Gaillard JP; Mani JC; Liautard J; Klein B; Brochier J Eur Cytokine Netw; 1999 Mar; 10(1):43-8. PubMed ID: 10210772 [TBL] [Abstract][Full Text] [Related]
16. Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines. Nakashima T; Kobayashi Y; Yamasaki S; Kawakami A; Eguchi K; Sasaki H; Sakai H Biochem Biophys Res Commun; 2000 Sep; 275(3):768-75. PubMed ID: 10973797 [TBL] [Abstract][Full Text] [Related]
17. Increased interleukin-6 levels, interleukin-6 receptor and gp130 expression in peripheral lymphocytes of patients with inflammatory bowel disease. Holub MC; Makó E; Dévay T; Dank M; Szalai C; Fenyvesi A; Falus A Scand J Gastroenterol Suppl; 1998; 228():47-50. PubMed ID: 9867112 [TBL] [Abstract][Full Text] [Related]
18. Effect of soluble interleukin-6 receptor alpha and interleukin-6 secreted by polymorphonuclear leukocytes on tumor necrosis factor-alpha expression and its production by peripheral blood mononuclear cells. Jablonska E Mediators Inflamm; 2002 Oct; 11(5):325-8. PubMed ID: 12467526 [TBL] [Abstract][Full Text] [Related]
19. The soluble IL-6 receptors: serum levels and biological function. Montero-Julian FA Cell Mol Biol (Noisy-le-grand); 2001 Jun; 47(4):583-97. PubMed ID: 11502067 [TBL] [Abstract][Full Text] [Related]
20. A combination of interleukin-6 and its soluble receptor impairs sperm motility: implications in infertility associated with endometriosis. Yoshida S; Harada T; Iwabe T; Taniguchi F; Mitsunari M; Yamauchi N; Deura I; Horie S; Terakawa N Hum Reprod; 2004 Aug; 19(8):1821-5. PubMed ID: 15166129 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]